CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy.
Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
癌症治疗领域近期发生了范式转变。除化疗、放疗和靶向特定信号通路的小分子药物等传统抗癌药物外,基于 T 细胞工程改造的细胞免疫疗法也已加入治疗体系。新型个体化细胞疗法迅速应用,得益于肿瘤免疫学、基因工程和细胞制备领域的科学进展;靶向 CD19 阳性恶性肿瘤的嵌合抗原受体(CAR)T 细胞治疗具有治愈潜力,是这一进展的典型例证。然而,许多患者获得临床获益的同时也可能付出代价。多达三分之一患者会出现显著毒性,且与强效免疫效应反应的诱发直接相关。最常见的免疫介导毒性是细胞因子释放综合征和免疫效应细胞相关神经毒性综合征。本综述讨论我们对其病理生理机制和临床表现的现有认识,以及用于预防和/或管理这些毒性的新型治疗方法的开发。
A paradigm shift has recently occurred in the field of cancer therapeutics. Traditional anticancer agents, such as chemotherapy, radiotherapy and small-molecule drugs targeting specific signalling pathways, have been joined by cellular immunotherapies based on T cell engineering.
The rapid adoption of novel, patient-specific cellular therapies builds on scientific developments in tumour immunology, genetic engineering and cell manufacturing, best illustrated by the curative potential of chimeric antigen receptor (CAR) T cell therapy targeting CD19-expressing malignancies.
However, the clinical benefit observed in many patients may come at a cost. In up to one-third of patients, significant toxicities occur that are directly associated with the induction of powerful immune effector responses. The most frequently observed immune-mediated toxicities are cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. This Review discusses our current understanding of their pathophysiology and clinical features, as well as the development of novel therapeutics for their prevention and/or management.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。